Drug-free haptic patches showed gains in sleep, pain, balance and strength in four trials

Four randomized, placebo-controlled trials presented at the World Congress of Psychiatry linked SuperPatch haptic patches to improvements in sleep, pain, balance and athletic performance. The findings point to a non-drug approach that researchers say may affect sensory pathways tied to symptom control.

Why it matters: - The results suggest a wearable, non-medication option could help with symptoms that often overlap in psychiatry and rehabilitation, including sleep disturbance, pain and balance problems. - The trials also point to a potential performance benefit in athletes, expanding the possible uses beyond symptom relief. - If replicated, the approach could offer a way to support care without systemic drug exposure.

What happened: - Research presented at the 26th WPA World Congress of Psychiatry in Stockholm, Sweden, reported positive results from four randomized, placebo-controlled trials of SuperPatch haptic patches. - The presentation, “Influencing and Enhancing Piezoelectric Channels via Haptic Technology: A Nonmedication Approach for Symptom Management,” was delivered by Peter Hurwitz, president of Clarity Science, LLC. - The four studies enrolled 319 total participants and were conducted under independent Institutional Review Board oversight by Advarra.

The details: - The technology uses a thin topical patch with an embedded pattern designed to deliver low-level stimulus to mechanoreceptors in the skin. - Investigators say the signal may engage PIEZO1 and PIEZO2 mechanosensitive ion channels and send signals through peripheral nerves to the spinal cord and brain. - The studies used active VTT patches made by The Super Patch Company or visually identical placebo patches. - Participants wore the patches for 7 to 14 days. - In the RESTORE sleep trial, 33 participants showed significant improvement in sleep quality, insomnia severity and time to fall asleep by Day 14, with p<0.001. - More than 83% of active-patch participants in RESTORE reported being “very” or “extremely” satisfied, compared with 40% in the placebo group. - In the pain trial, 148 participants had significant reductions in pain severity and interference, improved range of motion and improvement in every measured quality-of-life domain by Day 14, with p<0.05. - In the PROTECT balance trial, 68 adults ages 55 to 85 had a 4% reduction in “high-risk” fall classification and significant improvements in reaction time and time to stand and sit, with p<0.05. - In the placebo group in PROTECT, the changes were not significant. - In the POWER-UP athletic performance trial, 70 NCAA Division I athletes showed greater knee flexion strength gains in both legs than placebo, with p<0.001. - The strength gains increased with patch-wear time in POWER-UP. - Clarity Science said the studies were minimal-risk, double-blind trials. - The trials were funded by SRYSTY Holding Co. / The Super Patch Company, the patch manufacturer. - Clarity Science described the patches as a non-drug, non-invasive wearable technology designed to stimulate mechanoreceptors in the skin. - The company said its findings have been published in peer-reviewed scientific journals. - The Super Patch Company is based in Toronto and sells the patches through its website, superpatch.com. - Related source material includes a 2025 Cureus narrative review on piezo ion channels and a PubMed listing for the POWER-UP trial.

Between the lines: - The pitch here is broader than pain relief alone: the same sensory mechanism is being tested against sleep, balance and athletic output. - The mechanism claim is still a theory, but the trial design aims to connect that theory to measurable outcomes across different populations. - Funding from the patch manufacturer means the results may draw extra scrutiny, even with independent IRB oversight.

What's next: - The presentation could drive more interest in larger and longer trials that test whether benefits persist after the short study windows. - Further work will likely focus on whether the findings hold across different patient groups and real-world settings. - If confirmed, the patches could become a non-drug adjunct for clinicians looking to manage symptoms without added systemic side effects.

The bottom line: - Four small randomized trials suggest drug-free haptic patches may affect sleep, pain, balance and strength, but the results will need broader confirmation before they can reshape care.